| 順位 |
タイトル |
掲載号 |
著者 |
| 1 |
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial |
67.3 |
Ryusaburo Mori, Shigeru Honda, Fumi Gomi, Akitaka Tsujikawa, Hideki Koizumi, Haruka Ochi, Shino Ohsawa, Annabelle Ayame Okada & TENAYA and LUCERNE Investigators |
| 2 |
The Japan Glaucoma Society guidelines for glaucoma 5th edition |
67.2 |
Yoshiaki Kiuchi, Toshihiro Inoue, Nobuyuki Shoji, Makoto Nakamura, Masaki Tanito & Glaucoma Guideline Preparation Committee, Japan Glaucoma Society |
| 3 |
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial |
67.3 |
Masahiko Shimura, Shigehiko Kitano, Nahoko Ogata, Yoshinori Mitamura, Hideyasu Oh, Haruka Ochi, Shino Ohsawa, Akito Hirakata & YOSEMITE and RHINE Investigators |
| 4 |
Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan |
67.1 |
Yohei Hashimoto, Akira Okada, Hiroki Matsui, Hideo Yasunaga, Makoto Aihara & Ryo Obata |
| 5 |
A multicenter study of ocular inflammation after COVID-19 vaccination |
67.1 |
Yuta Yasaka, Eiichi Hasegawa, Hiroshi Keino, Yoshihiko Usui, Kazuichi Maruyama, Yuki Yamamoto, Toshikatsu Kaburaki, Daiju Iwata, Masaru Takeuchi, Sentaro Kusuhara, Hiroshi Takase, Kenji Nagata, Ryoji Yanai, Yutaka Kaneko, Chiharu Iwahashi, Atsuki Fukushima, Nobuyuki Ohguro, Koh-Hei Sonoda & JOIS Uveitis Survey Working Group |